These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 17943020)

  • 1. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients.
    Kato A; Tsuji T; Luo J; Sakao Y; Yasuda H; Hishida A
    Am J Nephrol; 2008; 28(1):115-21. PubMed ID: 17943020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin.
    Malyszko J; Malyszko JS; Kozminski P; Mysliwiec M
    Ren Fail; 2009; 31(10):876-83. PubMed ID: 20030521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum prohepcidin and hepcidin in hemodialyzed patients undergoing iron therapy.
    Malyszko J; Malyszko JS; Mysliwiec M
    Kidney Blood Press Res; 2009; 32(4):235-8. PubMed ID: 19713706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
    Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
    Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased hepcidin-25 and erythropoietin responsiveness in patients with cardio-renal anemia syndrome.
    Kato A
    Future Cardiol; 2010 Nov; 6(6):769-71. PubMed ID: 21142632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy.
    Weiss G; Theurl I; Eder S; Koppelstaetter C; Kurz K; Sonnweber T; Kobold U; Mayer G
    Eur J Clin Invest; 2009 Oct; 39(10):883-90. PubMed ID: 19563467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients.
    Arabul M; Gullulu M; Yilmaz Y; Eren MA; Baran B; Gul CB; Kocamaz G; Dilek K
    Med Sci Monit; 2009 Nov; 15(11):CR583-7. PubMed ID: 19865058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study.
    Li XY; Chang JP; Su ZW; Li JH; Peng BS; Zhu SL; Cai AJ; Zhang J; Jiang Y
    Ther Apher Dial; 2010 Jun; 14(3):308-14. PubMed ID: 20609184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients.
    Costa E; Pereira BJ; Rocha-Pereira P; Rocha S; Reis F; Castro E; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
    Am J Nephrol; 2008; 28(4):677-83. PubMed ID: 18354252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
    J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum pro-hepcidin as an indicator of iron status in dialysis patients.
    Tsuchihashi D; Abe T; Komaba H; Fujii H; Hamada Y; Nii-Kono T; Tanaka M; Fukagawa M
    Ther Apher Dial; 2008 Jun; 12(3):226-31. PubMed ID: 18503700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pro-hepcidin, its relation with indicators of iron metabolism and of inflammation in patients hemodialyzed treated or not with recombinant erythropoietin].
    Barrios Y; Espinoza M; Barón MA
    Nutr Hosp; 2010; 25(4):555-60. PubMed ID: 20694291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does hepcidin affect erythropoiesis in hemodialysis patients?
    Eleftheriadis T; Kartsios C; Liakopoulos V; Antoniadi G; Ditsa M; Papadopoulos C; Anifandis G; Skirta A; Markala D; Stefanidis I
    Acta Haematol; 2006; 116(4):238-44. PubMed ID: 17119323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease.
    Arabul M; Gullulu M; Yilmaz Y; Akdag I; Kahvecioglu S; Eren MA; Dilek K
    Clin Biochem; 2008 Sep; 41(13):1055-8. PubMed ID: 18571502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
    Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
    Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low serum levels of prohepcidin, but not hepcidin-25, are related to anemia in familial amyloidosis TTR V30M.
    Beirão I; Almeida S; Swinkels D; Costa PM; Moreira L; Fonseca I; Freitas C; Cabrita A; Porto G
    Blood Cells Mol Dis; 2008; 41(2):175-8. PubMed ID: 18544472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.